2 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Castration Levels of Testosterone: new trials by email Literature Review of Castration Levels of Testosterone trials Research Report on Castration Levels of Testosterone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Durvalumab, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Hormone-Resistant Prostate Cancer | Phase 2 | Withdrawn | University of Washington | 2018-05-15 | 2018-01-17 |
Microsatellite Instability (1) · Prostatic Neoplasms (1)
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Genomic Instability (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Decitabine (1) · Disulfides (1) · Immunoglobulin G (1) · Injections (1) · durvalumab (1) · enzalutamide (1)
Roswell Park Cancer Institute (1) · University of Washington (1)
United States (2)
Gurkamal Chatta (1) · Michael Schweizer (1)
P30CA015704 (1)